At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers
In Brief
A Phase 2 clinical trial evaluating Monovalent rAT, Monovalent rLukS-PV, and 3 other interventions for Staphylococcus Aureus. Completed, enrolled 176 participants across 2 sites.
Detailed Summary
This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body. The purpose of this study is to find the right dose of a new vaccine that is safe and produces a good immune response (how well your body recognizes and defends itself against harmful foreign substances). There are two Staphylococcus aureus toxoids (components or antigens) under investigation in this study; one of them is a protein known as rAT and the other is a protein known as rLukS-PV. They are being developed to see if they are effective at preventing infections caused by the bacteria Staphylococcus aureus.
Study Details
Timeline
Interventions
10, 25, 50 or 100 μg
10, 25, 50 or 100 μg
10, 25 or 50 μg
Placebo with adjuvant
Placebo saline